BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

BALAXI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+4.8%1-day move

₹22.90

prior close

₹22.96

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.8+3.0+3.0+3.0+4.8+9.8+13.1+17.5+16.4+20.1+19.7+22.1+6.5+4.8

Up moveDown movePending

AI summary

Balaxi Pharmaceuticals submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for Q4 FY26 (ending March 31, 2026). The certificate was issued by the company's Registrar and Share Transfer Agent, Aarthi Consultants Private Limited. The RTA confirmed compliance with dematerialization procedures — including processing, cancelling, and substituting ownership records for securities certificates received during January–March 2026 — within the mandated 15-day timeframe. This is a routine regulatory filing with no new information about company performance.

Likely market impact

No direct impact on stock price or shareholder value. This is a standard compliance submission confirming proper handling of dematerialization requests.